According to filings with the U.S. Securities and Exchange Commission, Avstera Therapeutics is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Karthik Musunuri played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company located in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera also is proud to be collaborating with top cancer researchers at both Georgetown University and the University of Pennsylvania. At Avstera, our primary focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond to existing therapies, or end up developing resistance to immunotherapy. With our proprietary pipeline of oncology programs, including an ultra-specific HDAC6i (AVS100), autologous HDAC6i activated macrophage-based cell therapy (AVS200), and mRNA cancer vaccine encoding TEM1 (AVS300), we will offer revolutionary solutions targeting solid tumors and addressing a significant unmet need for patients across all tumor types.

To learn more about Avstera Therapeutics, visit http://avstera.com/

Contact:
Karthik Musunuri, Chief Executive Officer
267-925-0454
https://www.linkedin.com/in/karthik-musunuri-666939179/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.